Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for Long-COVID Respiratory Symptoms
NCT04695704Phase 3Terminated
- Sponsor
- IDIAPJGol
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of montelukast in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by IDIAPJGol. Started Aug 2021; status: terminated.
02
Drugs
montelukast
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT04695704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695704.